---
document_datetime: 2023-09-21 21:18:45
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/pemetrexed-pfizer-epar-all-authorised-presentations_en.pdf
document_name: pemetrexed-pfizer-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8627947
conversion_datetime: 2025-12-21 16:05:13.819894
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| EU (MA) Number   | (Invented) name   | Strength   | Pharmaceutical Form                                     | Route of Administration    | Immediate Packaging   | Pack size   |
|------------------|-------------------|------------|---------------------------------------------------------|----------------------------|-----------------------|-------------|
| EU/1/17/1183/001 | Pemetrexed Pfizer | 100 mg     | Powder for concentrate for solution for infusion        | Intravenous use            | vial (glass)          | 1 vial      |
| EU/1/17/1183/002 | Pemetrexed Pfizer | 500 mg     | Powder for concentrate for solution for infusion        | Intravenous use            | vial (glass)          | 1 vial      |
| EU/1/17/1183/003 | Pemetrexed Pfizer | 1000 mg    | Powder for concentrate for solution for infusion longer | Intravenous use authorised | vial (glass)          | 1 vial      |